18.47
+0.22(+1.21%)
Currency In USD
| Previous Close | 18.25 |
| Open | 18 |
| Day High | 18.5 |
| Day Low | 17.39 |
| 52-Week High | 18.75 |
| 52-Week Low | 1.87 |
| Volume | 2.57M |
| Average Volume | 2.15M |
| Market Cap | 1.62B |
| PE | -17.93 |
| EPS | -1.03 |
| Moving Average 50 Days | 8.78 |
| Moving Average 200 Days | 5.26 |
| Change | 0.22 |
If you invested $1000 in Terns Pharmaceuticals, Inc. (TERN) since IPO date, it would be worth $1,004.35 as of November 09, 2025 at a share price of $18.47. Whereas If you bought $1000 worth of Terns Pharmaceuticals, Inc. (TERN) shares 3 years ago, it would be worth $3,189.98 as of November 09, 2025 at a share price of $18.47.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting
GlobeNewswire Inc.
Nov 03, 2025 2:05 PM GMT
Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host investor update call on December 8th at 4:30pm ET FOSTE
Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity
GlobeNewswire Inc.
Oct 21, 2025 8:05 PM GMT
Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participants during post-treatment follow-up period, two of
Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025
GlobeNewswire Inc.
Aug 21, 2025 8:05 PM GMT
Webinar to be held on Wednesday, September 3, 2025 at 4:30 p.m. ETFOSTER CITY, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a